Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AUPH
DateTimeSourceHeadlineSymbolCompany
02/05/202411:00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202411:00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202411:00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
16/04/202415:48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202411:00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202411:00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202421:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202421:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202421:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202421:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202413:30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
27/02/202413:30Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202421:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202411:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202411:00Business WireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder ValueNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/02/202420:27Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/02/202413:30Business WireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
05/01/202411:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/01/202411:00Business WireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
20/12/202311:00Business WireAurinia Submits IND Application to US Food & Drug Administration for AUR 200NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/11/202311:00Business WireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/11/202315:30Business WireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH